MAXCYTE INC COM STK USD0.01 (DI) news, videos and press releases
For more news please use our advanced search feature.
MAXCYTE INC COM STK USD0.01 (DI) - More news...
MAXCYTE INC COM STK USD0.01 (DI) - More news...
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
- MaxCyte Announces Retirement of Board Member Art Mandell
- MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
- MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
- MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
- MaxCyte to Participate in Two Upcoming Investor Conferences
- MaxCyte Appoints Cynthia Collins to its Board of Directors
- MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
- MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
- MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
- MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
- MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
- MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
- MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
- MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
- MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
- MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
- MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
- MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
- MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
- MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
- MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
- MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
- MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
- MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
- MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
- MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
- MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
- MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
- MaxCyte to Participate in Two Upcoming Investor Conferences
